Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 531592 | NSE Symbol : | ISIN : INE861N01036 | Industry : Trading |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
19-Mar-2025	24-Mar-2025	Others	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/03/2025 inter alia to consider and approve 1. To Review the performance of Non-Independent Directors & the Board as a whole; 2. To Review the performance of the Chairperson of the company taking into account the views of Executive Directors and Non-Executive Directors; 3. To assess the quality quantity and timeliness of flow of information between the management of the listed entity and the board of directors that is necessary for the board of directors to effectively and reasonably perform their duties. 4. Any other business with the permission of chair. Outcome of the Separate Meeting of Independent Directors of the Company Held on Monday, March 24, 2025. (As Per Bse Announcement Dated on 24.03.2025)
03-Feb-2025	10-Feb-2025	Quarterly Results	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2025 inter alia to consider and approve 1. To consider and approve Unaudited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report for the quarter and nine months ended 31st December 2024; 2. To consider any other business with the permission of a Chairman. Outcome of the Meeting of Board of Directors held on Monday, February 10, 2025. (As Per BSE Announcement dated on 10.02.2025)
05-Nov-2024	12-Nov-2024	Quarterly Results	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve 1. To consider and approve Un-audited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report for the quarter and half year ended September 30 2024; 2. To consider any other business with the permission of a Chairman. Outcome of the Meeting of Board of Directors held on Tuesday, November 12, 2024. (As Per BSE Announcement dated on 12.11.2024)
05-Aug-2024	13-Aug-2024	Quarterly Results	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve 1. To consider and approve Un-Audited Standalone and Consolidated Financial Results along with the Limited Review Report for the quarter ended June 30 2024; 2. Any other business with the permission of a Chairman. Outcome of the Meeting of Board of Directors held on Tuesday, August 13, 2024. (As Per BSE Announcement dated on 13.08.2024)
24-Jun-2024	27-Jun-2024	AGM	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/06/2024 inter alia to consider and approve 1.To Fix the Day Date Time and Mode of 32nd Annual General Meeting of the Company for the year ended March 31 2024 and approve Draft notice and Calendar of Events for the same. 2.To Fix the Cut- off date to determine the entitlement of voting rights of members for E-voting and to fix the commencement and closing date for E-voting. 3.To consider and approve the Directors Report for the year ended March 31 2024.4.To consider and approve Annual Report for Financial Year 2023-24. 5.To approve closure of Share Transfer Books & Register of Members for the 32nd Annual General Meeting. 6. To Consider and approve the appointment of Scrutinizer for E-voting at the ensuing 32nd Annual General Meeting. 7.Any other Matter with the permission of the Chairman. Outcome of the Meeting of Board of Directors held on Thursday, 27th June, 2024 at 02:30 P.M. (As Per BSE Announcement dated on 27.06.2024)
14-May-2024	24-May-2024	Accounts	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2024 inter alia to consider and approve 1. The Audited Standalone & Consolidated Financial Statements of the company for the Financial Year ended March 31 2024. 2. The Audited Standalone & Consolidated Financial Results of the company for Quarter and Financial Year ended March 31 2024. 3. To take on record the report of the Auditors on standalone and consolidated Financial Statements. 4. Any other Matter with the permission of the chairperson. Outcome of the Meeting of Board of Directors held on Friday, May 24, 2024 at 03.00 P.M. (As Per BSE Announcement dated on 24.05.2024)
26-Apr-2024	26-Apr-2024	Change in Directors	Intimation under Regulation 30 of SEBI (LODR) Regulation, 2015 for Appointment of Whole Time Director of the company.
21-Mar-2024	27-Mar-2024	Change in Directors	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/03/2024 inter alia to consider and approve 1. To consider and take on record the resignation of Mr. Ulhas Deosthale from the post of Whole-Time Director; 2. To consider and take on record the resignation of Ms. Heta Shah from the post of Company Secretary and Compliance Officer; 3. To consider and approve the appointment of Company Secretary and Compliance Officer in place of Ms. Heta Shah; 4. Any other business with the permission of Chairperson. Pursuant to Reg. 30 of SEBI (LODR) Reg. 2015, we wish to inform you that Mr. Hardik Makwana is appointed as the Company Secretary and Compliance Officer of the Company w.e.f. 27th March, 2024. (As per BSE Announcement Dated on 27/03/2024)
20-Mar-2024	26-Mar-2024	Others	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/03/2024 inter alia to consider and approve 1. To Review the performance of Non-Independent Directors & the Board as a whole; 2. To Review the performance of the Chairperson of the company taking into account the views of Executive Directors and Non-Executive Directors; 3. To assess the quality quantity and timeliness of flow of information between the management of the listed entity and the board of directors that is necessary for the board of directors to effectively and reasonably perform their duties. 4. Any other business with the permission of chair Outcome of the Separate Meeting of Independent Directors of the company held on Tuesday, March 26, 2024. (As per BSE Announcement Dated on 26/03/2024)
05-Feb-2024	12-Feb-2024	Quarterly Results	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve 1. To consider and approve the Un - audited Financial Results along with LRR for the quarter ended December 31 2023; 2. To confirm the closure of trading window from January 01 2024 till the end of 48 hours after the Financials Results are made public; 3. Any other business matter with the permission of chair. Financial Results for quarter ended December 31, 2023. Outcome of Board meeting on February 12, 2024 for filing quarterly financial results Revised filing of Outcome of Board Meeting on February 12, 2024 (As Per BSE Announcement dated on 12.02.2024)
01-Nov-2023	08-Nov-2023	Quarterly Results	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve 1. To consider & approve the un-audited Financial Results along with the Limited Review Report for the half-year ended September 30 2023 pursuant to Regulation 33 of Listing Obligation and Disclosure Requirement 2015. 2. To confirm Closure of trading window from 01st October 2023 till the end of 48 hours after the results are made public (both days inclusive) as per the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 for Directors and Designated Employees as defined in the 'Code of Conduct for Prevention of Insider Trading of the Company. 3. Any other business matter with the permission of the Chair. Pursuant to the provisions of Regulation 30 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors of our Company in their meeting held on Wednesday, 08th November, 2023 has: 1.Considered and approved and taken on records the Un-audited Financial Results along with Limited Review Report for the quarter and half year ended 30th September, 2023 prepared in terms of IND-AS, pursuant to Regulation 33 of (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2.Considered and approved and taken on records the Un-audited Statement of Assets and Liabilities for the quarter and half year ended 30th September, 2023. Pursuant to Reg. 30(2) of SEBI(LODR)Reg. 2015, we wish to inform you that the board meeting was held on 8-11-2023 to consider and approve the following : i) the un-audited financial results with LRR for the quarter and half year ended 30th September, 2023; ii) the un-audited Statement of Assets and Liabilities for the quarter and half year ended on 30th September, 2023. (As Per BSE Announcement Dated on 08/11/2023) Revised - financial results for the Board meeting held on 8th November, 2023 with the documents signed by the Whole-time Director of the Company and as complied with Reg. 33(2)(b). (As Per BSE Announcement Dated on 11/12/2023)
31-Aug-2023	31-Aug-2023	AGM	1. Considered and approved the Board Report for the year ended 31st March, 2023. 2. Considered and approved the notice of 31st Annual General meeting of the Members of the Company, which will be held on Saturday 23d September, 2023 at 09.30 A.M. at Kriish Cottage, C-101/201, Manas Building, Near St. Lawrence High School, Devidas Lane, Borivali (West), Mumbai 400103. 3.The Share Transfer Book and the Member''s Registers of the Company shall remain closed from 17th September, 2023 to 23rd September, 2023 (both days inclusive)in connection with the Annual General Meeting of the Company. 4. Further Company has fixed 16th September, 2023 as the CUT-OFF DATE 5. Considered and approved the appointment of M/S Jaymin Modi & Co as the Scrutinizer of the Annual General Meeting of the company to be held on Saturday 23rd September, 2023.
03-Aug-2023	11-Aug-2023	Quarterly Results	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve 1. To consider & approve the un-audited Financial Results along with the Limited Review Report for the Quarter ended June 30 2023 pursuant to Regulation 33 of Listing Obligation and Disclosure Requirement 2015. 2. To confirm Closure of trading window from 01st July 2023 till the end of 48 hours after the results are made public (both days inclusive) as per the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 for Directors and Designated Employees as defined in the 'Code of Conduct for Prevention of Insider Trading of the Company. 3. Any other business matter with the permission of the Chair. Pursuant to the provisions of Regulation 30 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors of our Company in their meeting held on Friday, 11th August, 2023 has: 1. Considered and Approved and taken on records the Un-Audited Financial Results along with Limited Review Report for the quarter ended 30th June, 2023 prepared in terms of IND-AS, pursuant to Regulation 33 of (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the same on your records. The Board Meeting commenced at 3.00 P.M. (IST) and concluded at 4:20 P.M. (IST) Pursuant to Reg. 30(2) of SEBI(LODR) Reg, 2015 we wish to inform you that the financial results are declared on 11th August, 2023 on Friday has: Considered and approved the un-audited Financial results along with limited review report for the quarter ended 30th June, 2023 prepared in terms of IND-AS, pursuant to reg. 33 of SEBI(LODR),Reg. 2015. (As Per BSE Announcement Dated on 11.08.2023)
30-May-2023	05-Jun-2023	Raising funds through Debt Instr.	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/06/2023 inter alia to consider and approve the proposal for raising of funds by issuance of equity share or convertible bonds or debentures or any other securities through permissible modes including but not limited to a rights issue preferential issue or qualified institutions placement as may be permitted under applicable law and subject to such regulatory/ statutory approvals as may be required and any other Matter with the permission of the Chairman. 1. The Board approved the issuance of Fully paid-up equity shares of face value of Rs. 1/- each of the Company on rights basis to eligible equity shareholders of the Company as on the record date (to be notified later), of an Issue size of upto Rs. 49 Crores (Rupees Forty-Nine Crores Only) (Rights Issue') 2. Further, the Board has constituted Rights Issue Committee 3. The Board Members has also approved the Draft Letter of Offer ('DLOF') for raising of funds through issuance and allotment of fully paid-up equity shares of Rs. 1/- each ('Equity Shares') to the eligible equity shareholders of the Company on a Rights basis, on such terms and at such price and ratio as may be decided by the Board (including Right Issue Committee) at a later date, as on the record date (to be notified later), for an amount upto Rs. 49 Crores (Rupees Forty-Nine Crores Only), subject to approvals (As per BSE Announcement Dated on 05/06/2023)
18-May-2023	26-May-2023	Accounts	Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2023 inter alia to consider and approve 1. To consider & approve the Audited Financial Results along with the Limited Review Report Statement of Assets and Liabilities and Cash flow Statement for the Quarter and Financial Year ended on March 31 2023 2. To consider and Approve the Audited Statement of Assets and Liabilities for the year ended 31st March 2023. 3. To confirm Closure of trading window from 03rd April 2023 till the end of 48 hours as per the Sebi (Prohibition of Insider Trading) Regulations 2015 for Directors and Designated Employees as defined in the 'Code of Conduct for Prevention of Insider Trading of the Company. 4. Appointment of M/s. Jaymin Modi & Co. Practicing Company Secretary as the Secretarial Auditor of the Company for the Financial Year 2023-2024. 5. Appointment of M/s. Meenakshi Manish Jain & Associates Practicing Chartered Accountants as the Internal Auditor of the Company for the Financial Year 2023-2024. 6. Any other business matter with the permission of the Chair. 1. Considered & Approved the Audited Financial Results (Standalone) for the quarter and year ended 31.03.2023. (Enclosed); 2. Considered & Approved the Audit Report (Standalone) issued by M/S. Abhishek S Tiwari & Associates, Chartered Accountant, Statutory Auditors of the Company in as per Regulation 33 of SEBI (LODR) Regulations, 2015 for the quarter and year ended 31.03.2023. (Enclosed)along with the declaration that the Report of Statutory Auditors is with unmodified opinion with respect to Standalone Audited Financial Results for the Quarter and year ended 31st March, 2023 is attached herewith. 3. The appointment of M/ s. Jaymin Modi & Co, Practicing Company Secretary as the Secretarial Auditor of the Company for financial year 2023-2024. 4. The appointment of M/ s. Meenakshi Manish Jain & Associates, Chartered Accountants, as an Internal Auditor of the Company for financial year 2023-2024. (As Per BSE Announcement dated on 26.05.2023)

1 2 3

LOGIN HERE

Genpharmasec Ltd

Board Meeting